Gastric cancer complicated by paraneoplastic neurological syndrome which presented with extremity numbness: a case report

Takuto Yoshida1, Hideki Kawamura1*, Kazuhiro Mino1, Yuji Konishi1, Tomoya Saito1, Yuichi Shimizu2 and Akinobu Taketomi3

Abstract

Background: Paraneoplastic neurological syndromes refer to a group of neurological disorders, which occur as distant effects of malignant tumors and are not caused by metastasis, nutritional disorders, or side effects of antitumor drugs.

Case presentation: A 70-year-old woman complained of a 1-month history of extremity numbness. Upon presentation to our hospital, she had worsening numbness, and experienced staggering and falling. Physical examination revealed diminished tendon reflexes in both lower limbs, stocking and glove-type abnormal sensation, and left-sided dominant high-steppage gait due to weakness of the bilateral tibialis anterior muscles. Blood tests indicated anemia, and upper gastrointestinal endoscopy revealed gastric cancer, leading to laparoscopic distal gastrectomy. A nerve conduction velocity test showed demyelinating peripheral neuropathy. Further blood tests and imaging studies ruled out nutritional disorders, such as vitamin deficiency, diabetes-related diseases, connective tissue diseases, and central nervous system metastasis, leading to the suspicion of paraneoplastic neurological syndrome. After laparoscopic distal gastrectomy, the progression of symptoms stopped, and with intravenous high-dose immunoglobulin and steroid therapy, the symptoms improved to only minor numbness in the peripheral limbs as of the 18-month follow-up. As of the 2-year follow-up, there has been no cancer recurrence or metastasis.

Conclusions: When paraneoplastic neurological syndrome is suspected, early diagnosis and a multidisciplinary approach, including surgical treatment, are important before irreversible neurological damage occurs.

Keywords: Gastric cancer, Paraneoplastic neurological syndrome, Neurological disorder, Numbness

Background

Paraneoplastic neurological syndromes (PNS) refer to a group of neurological disorders, which occur as distant effects of malignant tumors and are not caused by metastasis, nutritional disorders, or side effects of antitumor drugs. Here, we report a case of gastric cancer with PNS diagnosed based on numbness in the extremities. We also review relevant previous reports and summarize case patient findings and outcomes from the literature and the current case in a table (Table 1).

Case presentation

A 70-year-old woman presented with a 1-month history of bilateral lower extremity numbness with left-sided predominance. She had a history of hypertension and insomnia, and was taking candesartan and triazolam.
Blood tests showed a hemoglobin (Hb) level of 7.8 mg/dl, and an upper gastrointestinal endoscopy revealed a type 3 lesion on the posterior wall of the lower part of the stomach, which was biopsied and diagnosed as adenocarcinoma (Fig. 1). At that time, numbness had appeared in both hands. All symptoms gradually worsened, resulting in staggering, falling, and difficulty in walking. Physical examination revealed diminished tendon reflexes in the lower extremities and decreased muscle strength (manual muscle test [MMT] 3/5) of the bilateral tibialis anterior muscles. The Romberg sign was fair, and a bilateral steppage gait was observed. Blood test results were: vitamin B12, 197; antinuclear antibody (ANA) titer, < 40; anti-deoxyribonucleic acid (DNA) antibody, < 2.0; anti-SS-A antibody, < 1.0; anti-SS-B antibody, < 1.0; soluble IL-2 receptor, 321; myeloperoxidase–anti-neutrophil cytoplasmic antibodies (MPO–ANCA), < 1.0; and proteinase 3–anti-neutrophil cytoplasmic antibodies (PR3–ANCA), < 1.0. Cerebrospinal fluid (CSF) examination revealed glucose of 58 mg/dl, cell count

Table 1  Description of case studies from the literature

| References | Age/sex | Time to diagnosis | Clinical syndrome | Histological type | Onconeural antibody | Neurological outcome | Oncological outcome |
|------------|---------|------------------|------------------|------------------|---------------------|----------------------|---------------------|
| Balducci et al. [18] | 58/male | 1 month | PCD | Neuroendocrine | N/A | Partial response (OP + IT) | Disease free (18 months) |
| Kikuchi et al. [19] | 63/male | N/A | PCD | Neuroendocrine | Ri | N/A | N/A |
| Baraller et al. [20] | 59/male | 1 month | OMS | N/A | N/A | No response (IT) | Dead (6 months) |
| Meglic et al. [21] | 73/male | 4 months | PCD | Poorly | Yo | No response (OP) | Disease free (6 months) |
| Wada et al. [22] | 64/male | 9 months | PLE | Neuroendocrine | Not detected | No response (CT) | Dead (19 months) |
| Tanaka et al. [23] | 77/male | 2 months | PLE | N/A | GluR | Progressive (No treatment) | Alive (3 months) |
| Goto et al. [24] | 71/male | -7 months | PCD | N/A | Yo | No response (IT) | Disease free (2 months) |
| Yasuda et al. [25] | 72/female | 24 months | SSN, SM | Signet-ring cell | N/A | Complete response (OP + IT) | Disease free (36 months) |
| Murakami et al. [26] | 63/female | 5 months | SSN | Neuroendocrine moderate | Hu | Partial response (OP + CT + IT) | Disease free (31 months) |
| Taketa et al. [3] | 72/male | 0.5 months | PLE | Neuroendocrine | N-type VGCC | Complete response (OP + CT) | Disease free (15 months) |
| Biotti et al. [26] | 61/male | 3 months | PLE | Adenocarcinoma | Ma | Partial response (CT + IT) | Alive (9 months) |
| Al-Harbi et al. [28] | 38/female | 2 months | PLE | Neuroendocrine | N/A | Partial response (IT) | N/A |
| Bataller et al. [29] | 59/male | N/A | OMS | Adenocarcinoma | N/A | No response (IT) | Dead (6 months) |
| Uneno et al. [30] | 71/male | N/A | PLE | Adenocarcinoma | Hu | Partial response (CT) | Dead (14 months) |
| Our case | 70/female | 1 months | LEMS | Adenocarcinoma | N/A | Complete response (OP + IT) | Disease free (24 months) |

N/A not applicable; PCD paraneoplastic cerebellar degeneration; OMS opsoclonus–myoclonus; PLE paraneoplastic limbic encephalitis; SSN subacute sensory neuropathy; SM systematic myositis; VGCC voltage-gated calcium channel; LEMS Lambert–Eaton myasthenic syndrome; OP operation; IT immunotherapy; CT chemotherapy; GluR glutamate receptor

Fig. 1 Gastric fiber. Type 3 tumor in posterior wall of the lower part of the stomach
(1/3, mononuclear cells 100%), protein 122 mg/dl, and Cl 125 mEq/l. PNS and chronic inflammatory demyelinating polyneuropathy were considered as differential diagnoses. Brain magnetic resonance imaging (MRI) did not reveal any findings suggestive of brain metastasis (Fig. 2A). Spinal MRI showed kyphotic deformity of C4 and narrowing of the spinal canal around C4/5, but no obvious spinal cord compression or abnormal intramedullary signals (Fig. 2B). Contrast-enhanced computed tomography (CT) of the abdomen revealed wall thickening with contrast effect on the lateral side of the greater curvature of the stomach and enlarged lymph nodes in the surrounding area, suggesting metastasis (Fig. 3). Nerve conduction velocity testing showed decreased amplitude of complex-type action potentials (CMAP) in the ulnar and peroneal nerves and no derivation of F waves. A laparoscopic distal gastrectomy was performed. The pathological results showed a 45 × 40 mm type 3 lesion on the posterior wall of the mid-gastric body. Histologically, the lesion appeared to be a moderately to poorly differentiated adenocarcinoma, with tumor cells infiltrating the subserosal layer and invading lymphatic vessels and veins (Fig. 4). Based on the pathological examination, the final diagnosis was T3N1M0 Stage IIIB, according to the Japanese Classification of Gastric Carcinoma (JCGC) (3rd English Edition) [1]. The postoperative course was uneventful; intravenous high-dose immunoglobulin therapy (IVIG) was started on the third postoperative day, and oral steroids were started on the 14th postoperative day. After rehabilitation, the patient was able to walk with a walker and the numbness in the limbs disappeared, and she was discharged on the 28th day after surgery. Her advanced age and prolonged hospitalization resulted in a marked decline in her physical activity, and we determined that adjuvant chemotherapy was not indicated according to her request. Steroids were then started at 25 mg but reduced by 5 mg every 4 weeks and continued at 10 mg for some time. At 8 months postoperatively, we decreased the dose to 5 mg, and after that, we reduced the steroid volume by 1 mg every 4 weeks, and the steroids were terminated at 18 months postoperatively. With this dosage regimen, the patient was able to walk with a cane 1 month after discharge from the hospital, and another month after that, he no longer needed a cane. The decreased deep tendon reflexes and mild steppage gait remained for some time but completely disappeared at 18 months postoperatively. Two years
have passed since the surgery without any recurrence or metastasis.

Discussion

PNS are seen in patients with malignant tumors and are exclusive of tumor invasion and metastasis, nutritional and metabolic disturbances, and side effects of antitumor drugs. PNS are stated to be “remote effects of cancer on the nervous system” [2]. Broadly, PNS refer to the remote effects of malignancy on organs and tissues other than the primary tumor site. However, in a narrower sense, the syndromes do not include metabolic conditions, such as hypercalcemia associated with malignancy. Rather, only immune-mediated neurological disorders are included. Among patients with malignant tumors, PNS are more common in those with small cell carcinoma of the lung; the incidence in other solid tumors is much lower than 1%, and it is considered a rare condition [3]. PNS can present with the following neurological manifestations: encephalomyelitis, limbic encephalitis, paraneoplastic cerebellar degeneration, oposcolonus/myoclonus, sensory neuropathy, chronic intestinal pseudo-obstruction, and Lambert–Eaton myasthenic syndrome (LEMS), and are called “classical syndromes” which have a robust association with tumors [4, 5]. In the current case, the patient had muscle weakness and decreased deep tendon reflexes in the lower extremities, suggesting Lambert–Eaton myasthenic syndrome. Lambert–Eaton myasthenic syndrome is often associated with small cell carcinoma of the lung but is also seen in patients with gastric cancer and thymoma [6]. Antibodies against P/Q-type voltage-gated calcium channels (VGCCs) and other voltage-gated calcium channels are common [7]; however, antibodies against synaptotagmin [8], amphiphysin [9], and CRMP-5 [3] have also been reported. These antibodies were not detected in this case.

Approximately two-thirds of patients suspected of having PNS have neurological symptoms, but no diagnosis of cancer [10]. In a review of 10 patients with PNS, Taketa et al. reported that, on average, neurological symptoms were present approximately 6 months before the diagnosis of cancer [11]. If PNS is suspected in such patients, it is necessary to measure PNS-related antibodies and search for cancer. Although the presence of PNS-related antibodies is highly suggestive of the presence of tumors, the positivity rate is less than 1% [12, 13]. Therefore, even if the test is negative, the patient should be retested at 3 and 6 months. In addition, the European Federation of Neurological Societies (EFNS) Task Force recommends periodic searches every 6 months for 4 years [14]. When a patient diagnosed with cancer develops neurological symptoms, the diagnosis of PNS is made after ruling out metastasis to the central nervous system via imaging and CSF studies. There are three main groups of PNS-associated antibodies: “well-characterized onconeural antibodies,” such as anti-Hu and anti-Yo antibodies, in which neurological symptoms are strongly considered paraneoplastic and are strongly associated with certain cancers; a group that is not necessarily associated with the presence of cancer; and a group known as “partially-characterized onconeural antibodies,” in which significance as markers of PNS has been confirmed, although the characteristics of the corresponding antigen are not precise [4]. In the current case, neurological symptoms preceded the disease. However, anemia was also observed in blood tests, which led to upper gastrointestinal endoscopy and early diagnosis. Although specific antibodies were negative, metastasis to the central nervous system was ruled out, leading to an early diagnosis of PNS.

The EFNS Task Force considers the search for and treatment of malignancy, immunosuppression, and symptom control as the mainstays of therapy [14]. Resection of malignant tumors is the most effective treatment to control the progression of neurological symptoms and, in particular, to restore function [10, 15, 16].
Immunosuppressive treatment includes plasma exchange and large doses of immunoglobulins, corticosteroids, rituximab, and tacrolimus [17]. PNS often lead to irreversible neurological damage by the time of therapeutic intervention, and the treatment prognosis is generally poor. In several reports, PNS have been caused by gastric cancer, including our case (Table 1). Taketa et al. [10] reported the following characteristics of gastric cancer associated with PNS: first, approximately half of the cases are neuroendocrine tumors (NET) or undifferentiated carcinomas, such as signet ring cell carcinoma derived from neuroendocrine tumors. In the present case, postoperative pathological examination revealed the presence of poorly differentiated adenocarcinoma, which is consistent with previous reports. Second, although NET is usually considered to have a poor prognosis, when accompanied by PNS, the prognosis is relatively good, with an excellent response to treatment. This is due to the expression of major histocompatibility complex (MHC) class 1 and non-amplification of the myc gene. To date, the current case is under observation without recurrence. The third point is that it takes an average time of 5.8 months from the onset of symptoms to diagnosis. However, in the present case, gastric cancer was diagnosed within approximately 1 month from the onset of symptoms, and we were able to intervene early with treatment. In addition to surgical intervention, there are many reports of patients being treated with chemotherapy and immunosuppressive agents that have shown therapeutic efficacy. However, although there are few case reports of complete response, in the current case, early diagnosis and resection of the primary lesion, followed by prompt introduction of immunosuppressive agents, may have contributed to the disappearance of neurological symptoms. Conversely, considering approximately 2 years of oral immunosuppressive medication was necessary to achieve complete resolution of symptoms, the importance of early diagnosis is apparent. When PNS is suspected, early diagnosis, early surgery, and immunosuppressive therapy are considered necessary.

Conclusions
We experienced a patient with gastric cancer complicated by rare PNS. When PNS is suspected, early diagnosis and treatment are important before irreversible neurological damage occurs.

Abbreviations
PNS: Paraneoplastic neurological syndrome; MMT: Manual muscle test; ANA: Antinuclear antibody; DNA: Deoxyribonucleic acid; MPO–ANCA: Myeloperoxidase–anti-neutrophil cytoplasmic antibodies; PR3–ANCA: Proteinase 3–anti-neutrophil cytoplasmic antibodies; MRI: Magnetic resonance imaging; CSF: Cerebrospinal fluid; CT: Computed tomography; CMAP: Complex-type action potentials; IVG: Intravenous high-dose immunoglobulin therapy; LEMS: Lambert–Eaton myasthenic syndrome; VGCC: Voltage-gated calcium channel; NET: Neuroendocrine tumors; EFNS: The European Federation of Neurological Societies; MHC: Major histocompatibility complex.

Acknowledgements
We would like to thank Elsevier Language Editing Services for their English proofreading.

Author contributions
TY reported the case and wrote the manuscript. HK, KM, YS, TS, and YS were involved in the patient treatment and helped draft the manuscript. HK and AT critically revised the manuscript. All authors have read and approved the final manuscript.

Funding
No grant support or funding from public institutions or private enterprises was received for this case report.

Availability of data and materials
The data set supporting the conclusions of this article is included in the article.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patient for the publication of this case report and accompanying images.

Competing interest
The authors declare that they have no competing interests.

Author details
1 Department of General Surgery, Hokkaido Medical Center, 1-1, S-7 Yamanote, Nishi-ku, Sapporo 063-0005, Japan. 2 Department of Gastroenterology, Hokkaido Medical Center, 1-1, S-7 Yamanote, Nishi-ku, Sapporo 063-0005, Japan. 3 Department of Gastroenterological Surgery 1, Graduate School of Medicine, Hokkaido University, N-15, W-7, Kita-ku, Sapporo 060-8638, Japan.

Received: 6 March 2022   Accepted: 12 April 2022
Published online: 28 April 2022

References
1. Sano T, Kodera Y. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
2. Posner JB, Dalmout D. Paraneoplastic syndromes. Curr Opin Immunol. 1997;5:725–9.
3. Tanaka K. Paraneoplastic neurological syndromes with reference to anti-neuronal autoantibodies. Clin Neurol. 2010;50:371–8.
4. Graus F, Delattre JY, Antoine JC, Dalmau J, Gometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–40.
5. Inuzuka T, Hayashi Y, Kimura A. Paraneoplastic neurological syndrome—update. Rinsho shinkeigaku = Clin Neurol. 2011;51(11):834–7.
6. O’Neill JH, Murray NW, Newsom-Davis J. The Lambert–Eaton myasthenic syndrome: a review of 50 cases. Brain. 1988;111:779–96. https://doi.org/10.1093/brain/111.3.577.
7. Lennon VA, Kryzer TJ, Griesmann GE, O’Sullivanahan PE, Windebank AJ, Woppmann A, et al. Calcium-channel antibodies in the Lambert–Eaton syndrome: a review of 50 cases. Brain. 1995;332:1467–75.
8. Martin-Moutot N, el Far O, Leveque C, David P, Marqueze B, Lang B, et al. Synaptotagmin: a Lambert–Eaton myasthenic syndrome antigen that associates with presynaptic calcium channels. J Physiol Paris. 1993;87:37–41.
9. Saiz A, Dalmau J, Butler MH, Chen Q, Delattre JY, De Camilli P, et al. Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry. 1999;66:214–7.

10. Candler PM, Hart PE, Barnett M, Weil R, Rees JH. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry. 2004;75:1411–5.

11. Taketa T, Ohigashi S, Suzuki K, Sudo K, Shiozaki H, Suzuki A, et al. Paraneoplastic neurological syndromes associated with gastric cancer: a case report and review of the literature. J Clin Gastroenterol. 2012;5:355–60.

12. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56:715–9.

13. Croft PB, Wilkinson M. The incidence of carcinomatous neuromyopathy in patients with various types of carcinoma. Brain. 1965;88:427–34. https://doi.org/10.1093/brain/88.3.427.

14. Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13:682–90.

15. Douglas CA, Ellershaw J. Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer. Palliat Med. 2003;17:638–9.

16. Keime-Guibert F, Graus F, Broet P, René R, Molinuevo JL, Ascaso C, et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology. 1999;53:1719–23.

17. Keime-Guibert F, Graus F, Fleury A, René R, Honnorat J, Broet P, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68:479–82.

18. Baldacci G, Frontoni M, Bocchetti T, Angelini D, Di Giacomo G, Ziparo V. Malignant gastric carcinoid and paraneoplastic cerebellar degeneration. Eur J Surg. 1999;165:1193–6.

19. Kikuchi H, Yamada T, Okamoto A, Hara H, Taniwaki T, Shigeto H, et al. Anti-Ri-associated paraneoplastic cerebellar degeneration without opsoclonus in a patient with a neuroendocrine carcinoma of the stomach. Fukuoka Igaku Zasshi. 2000;91:104–9.

20. Goto A, Kusumi M, Wakutani Y, Nakashima K. Anti-Yo antibody associated paraneoplastic cerebellar degeneration with gastric adenocarcinoma. J Neurol Sci. 2001;185:135–8.

21. Yasuda C, Yakushiji Y, Tokunaga O, Hara H, Nishino I. Case of systemic myositis and subacute sensory neuropathy concomitant with signet-ring cell carcinoma. Rinsho Shinkeigaku. 2010;50:246–51.

22. Murakami H, Rino Y, Yamakawa S, Baba Y, Sekiguchi T, Yukiwa N, et al. Paraneoplastic neurological syndrome in a patient with gastric cancer. Gastric Cancer. 2010;13:204–8.

23. Biotti D, Viacava A, Oliver N, Tilikete C, Rogemond V, Honnorat J, et al. Opsoclonus, limbic encephalitis, anti-Ma2 antibodies and gastric adenocarcinoma. Eur J Neurol. 2012;19:e144–5.

24. Biotti D, Viacava A, Oliver N, Tilikete C, Rogemond V, Honnorat J, et al. Opsoclonus, limbic encephalitis, and anti-Ma2 antibodies in a patient with gastric adenocarcinoma. Eur J Neurol. 2012;19:e144–5.

25. Biotti D, Viacava A, Oliver N, Tilikete C, Rogemond V, Honnorat J, et al. Opsoclonus, limbic encephalitis, anti-Ma2 antibodies and gastric adenocarcinoma. Eur J Neurol. 2012;19:e144–5.

26. Biotti D, Viacava A, Oliver N, Tilikete C, Rogemond V, Honnorat J, et al. Opsoclonus, limbic encephalitis, anti-Ma2 antibodies and gastric adenocarcinoma. Eur J Neurol. 2012;19:e144–5.

27. Biotti D, Viacava A, Oliver N, Tilikete C, Rogemond V, Honnorat J, et al. Opsoclonus, limbic encephalitis, anti-Ma2 antibodies and gastric adenocarcinoma. Eur J Neurol. 2012;19:e144–5.

28. Al-Harbi T, Al-Sarawi A, Binfalah M, Dermime S. Paraneoplastic neuromyelitis optica spectrum disorder associated with stomach carcinoma. Hematol Oncol Stem Cell Ther. 2014;7:116–9.

29. Bataller L, Graus F, Saiz A, Vilchez JJ. Spanish Opsoclonus-Myoclonus Study Group. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124:437–43.

30. Uneno Y, Yokoyama A, Nishikawa Y, Funakoshi T, Ozaki Y, Aoyama I, et al. Paraneoplastic limbic encephalitis in a human epidermal growth factor receptor-2-positive gastric cancer patient treated with trastuzumab-combined chemotherapy: a case report and literature review. Intern Med. 2016;55:2605–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.